LORI CRAIG, APRN-CNP
Nurse Practitioner · OKLAHOMA CITY, OK
Individual Active NPI 1003468745
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,044 | 735,325 | $25,285,238 | $12,554,757 | $9,984,756 |
| 2023 | 921 | 461,415 | $17,293,448 | $8,764,338 | $6,957,531 |
| 2022 | 308 | 77,748 | $3,413,523 | $1,618,785 | $1,289,841 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 195,159 | $1 | $1 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 73,710 | $17 | $14 |
| J1306 | Injection, inclisiran, 1 mg | 69,580 | $12 | $9 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 56,070 | $11 | $8 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 47,400 | $21 | $17 |
| J0897 | Injection, denosumab, 1 mg | 43,260 | $26 | $20 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 40,500 | $1 | $1 |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 25,700 | $11 | $9 |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | 12,300 | $16 | $13 |
| J3245 | Injection, tildrakizumab, 1 mg | 9,500 | $135 | $107 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 5,060 | $28 | $22 |
| 96372 | Injection of drug or substance under skin or into muscle | 2,103 | $11 | $9 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Nurse Practitioner | 363L00000X | ✓ | R009034 | OK |
| Nurse Practitioner | 363L00000X | APN.23047 | SC |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Nurse Practitioner providers in Oklahoma
- NPI 1871175166
- NPI 1295197713
- NPI 1912675224
- NPI 1275095986
- NPI 1104273192
- NPI 1376042556
- NPI 1619524683
- NPI 1821751694
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.